Evidence map›Paper›PMID 30617738›Full record

ArticleEndocrine2019

Effects of growth hormone on hepatic insulin sensitivity and glucose effectiveness in healthy older adults.

Lala Forrest, Caroline Sedmak, Shanaz Sikder, Shivraj Grewal, S Mitchell Harman, Marc R Blackman, Ranganath Muniyappa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. The acromegaly lipodystrophy.Frontiers in endocrinology · 2022
    Article
  3. Effect of growth hormone on insulin signaling.Molecular and cellular endocrinology · 2020
    Review
  4. Article
  5. Insulin Resistance in Patients With Acromegaly.Frontiers in endocrinology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lala ForrestClinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Caroline SedmakClinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Shanaz SikderClinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Shivraj GrewalClinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
S Mitchell HarmanEndocrinology Section, Department of Medicine, Phoenix VA Health Care System, Phoenix, AZ, USA.
Marc R BlackmanResearch Service, Veterans Affairs Medical Center, Washington, DC, USA.
Ranganath MuniyappaClinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. muniyapr@mail.nih.gov.ORCID http://orcid.org/0000-0003-4198-1055
National Institutes of Health · USGeorgetown University · USPhoenix VA Health Care System · US

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
Biobehavioral Studies of Obesity, Weight loss and RecidivismZIADK075007 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MUNIYAPPA, RANGANATH · 2009 to 2025
$13.8M
Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK075007NCATS NIH HHS UL1 TR001409NIDDK NIH HHS The Intramural ProgramNIH HHS RO-1 AG11005
6 · The paper itself

Abstract

purposeGrowth hormone (GH) replacement decreases insulin sensitivity in healthy individuals. However, the effects of GH on organ-specific insulin sensitivity and glucose effectiveness are not well characterized. The purpose of this study was to evaluate the effects of GH administration for 26 weeks on muscle and hepatic insulin sensitivity and glucose effectiveness in healthy older individuals.

methodsThis report is from a 26-week randomized, double-blind, placebo-controlled parallel-group trial in healthy, ambulatory, community-dwelling older women and men. We compared surrogate indices of insulin sensitivity [quantitative insulin-sensitivity check index (QUICKI), muscle insulin sensitivity index (MISI), hepatic insulin resistance index (HIRI)] and glucose effectiveness [oral glucose effectiveness index (oGE)] derived from oral glucose tolerance tests (OGTTs) in subjects before and after 26 weeks of administration of GH (n = 17) or placebo (n = 15) as an exploratory outcome.

resultsGH administration for 26 weeks significantly increased fasting insulin concentrations and HIRI but did not significantly change MISI or oGE compared to placebo.

conclusionsGH administration for 26 weeks in healthy older subjects impairs insulin sensitivity in the liver but not skeletal muscle and does not alter glucose effectiveness.

Indexed as

Insulin ResistanceAgedAged, 80 and overFemaleGlucose Tolerance TestGrowth HormoneHormone Replacement TherapyHumansLiverMaleMuscle, SkeletalGrowth HormoneAgingGlucose effectivenessGrowth hormoneInsulin resistance

Identifiers

PMID30617738
PMCPMC6420854
OpenAlexW2910604719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.